文献速递免疫规划传染病防控与疫情报告

BCG初免联合Esx-5分泌系统缺失突变体加强可提升结核保护

BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis.
PubMed 文献 · Vaccine · 2020-09-23

研究构建了结核分枝杆菌Esx-5型VII分泌系统完全缺失突变体(Mtb Δesx-5),在免疫缺陷小鼠中显示高度减毒且安全。以该突变体加强BCG初免免疫,在小鼠和豚鼠模型中改善了对高毒力Mtb临床株的保护。增强的保护与肺部中央记忆T细胞、滤泡辅助T细胞和活化单核细胞流入增加相关,而表达耗竭标志物的T细胞数量较低。

要点

  • Mtb Δesx-5在免疫缺陷小鼠中高度减毒且安全。
  • BCG初免加Mtb Δesx-5异源加强在小鼠和豚鼠中提升保护。
  • 保护增强伴随TCM、TFH和活化单核细胞肺部流入增加。

核心结论

  • 以Mtb Δesx-5加强BCG初免免疫是改善抗Mtb保护性免疫的潜在策略。

研究设计与样本

  • 研究构建Mtb Esx-5型VII分泌系统完全缺失突变体(Mtb Δesx-5),在免疫缺陷小鼠中评估安全性与减毒程度。
  • 以Mtb Δesx-5作为疫苗候选加强BCG初免免疫,在小鼠和豚鼠TB模型中测试对高毒力Mtb菌株的保护。

主要发现

  • Mtb Δesx-5在免疫缺陷小鼠中高度减毒且安全。
  • BCG初免加Mtb Δesx-5加强在小鼠和豚鼠模型中改善了对高毒力Mtb菌株的保护。
  • 异源BCG初免加Mtb Δesx-5加强方案增强的保护与肺部中央记忆T细胞、滤泡辅助T细胞和活化单核细胞流入增加相关。
  • 接种动物中表达耗竭标志物的T细胞数量较低。

临床怎么用

  • 该prime-boost策略目前仅为临床前证据,尚不能直接用于人群接种决策。

局限性

  • 原文指出需进一步阐明该新型初免-加强方案的作用机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although vaccination with BCG prevents disseminated forms of childhood tuberculosis (TB), it does not protect against pulmonary infection or Mycobacterium tuberculosis (Mtb) transmission. In this study, we generated a complete deletion mutant of the Mtb Esx-5 type VII secretion system (Mtb Δesx-5). Mtb Δesx-5 was highly attenuated and safe in immunocompromised mice. When tested as a vaccine candidate to boost BCG-primed immunity, Mtb Δesx-5 improved protection against highly virulent Mtb strains in the murine and guinea pig models of TB. Enhanced protection provided by heterologous BCG-prime plus Mtb Δesx-5 boost regimen was associated with increased pulmonary influx of central memory T cells (TCM), follicular helper T cells (TFH) and activated monocytes. Conversely, lower numbers of T cells expressing exhaustion markers were observed in vaccinated animals. Our results suggest that boosting BCG-primed immunity with Mtb Δesx-5 is a potential approach to improve protective immunity against Mtb. Further insight into the mechanism of action of this novel prime-boost approach is warranted.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tiwari S, Dutt TS, Chen B, et al. BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis. Vaccine. 2020. PMID: 32978002. doi:10.1016/j.vaccine.2020.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。